Patient must be planned to begin initial therapy, or completely resected before or after receiving adjuvant therapy
For patients with NSCLC, EGFR and KRAS genotype may be known or unknown
For patients with melanoma, BRAF and NRAS genotype may be known or unknown
For patients without tumor genotyping, there must be a plan for genotyping including either:
* Archived tumor tissue available and planned for genotyping
* A biopsy at some future time is anticipated and will be available for genotyping
Cohort 2: Cancers with acquired resistance to targeted therapy
One of the following diagnoses:
* Cohort 2A (CLOSED):
---Advanced NSCLC harboring a known EGFR mutation
* Cohort 2B:
* Advanced NSCLC harboring a targetable genotype other than EGFR
* Advanced melanoma harboring a known tumor genotype
Clinical determination of progression targeted therapy, as evidence by plans to start a new systemic treatment regimen, or obtain a biopsy to plan a new treatment regimen
* New systemic treatment regimen planned OR
* Re-biopsy for resistance genotyping planned
Note, date of targeted therapy start and clinical progression must be provided
Cohort 3: Cancers with a known genotype starting palliative systemic therapy
Cohort 3A (CLOSED):
Advanced NSCLC harboring one of the following mutations:
* EGFR exon 19 deletion
* EGFR L858R
* EGFR T790M
* KRAS G12X
* BRAF V600E
Patients must be initiating palliative systemic therapy, either on or off a clinical trial
Cohort 4: Paired plasma NGS and ddPCR
Cohort 4A (CLOSED):
* Advanced NSCLC, newly diagnosed or with progression following treatment.
* Biopsy tissue must be available or a biopsy planned and one of the following:
* Genotyping must have been performed previously
* Genotyping must be in progress
* A plan must exist to order genotyping on existing tissue or a planned re-biopsy
* Patient must not be eligible to enroll in cohort 1A or 2A due to:
You may not be if
* Eligible for cohort 1A or 2A but cohort has closed
Cohort 4B: Undergenotyped NSCLC
* Advanced NSCLC, newly diagnosed or with progression following treatment.
* No known targetable genotype on prior tumor genotyping
* Biopsy planned for tumor genotyping
Cohort 4C: EGFR-mutant NSCLC with acquired resistance
* Advanced EGFR-mutant NSCLC with progression on EGFR TKI
* Biopsy planned for resistance genotyping (e.g. T790M, etc)
